Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: A meta-analysis

被引:59
作者
Ge, Lei [1 ]
Wang, Hai-Jiang [1 ]
Yin, Dong [1 ]
Lei, Cheng [1 ]
Zhu, Jin-Feng [1 ]
Cai, Xiao-Hui [1 ]
Zhang, Guo-Qing [1 ]
机构
[1] Xinjiang Med Univ, Dept Gastrointestinal Surg, Tumor Hosp, Urumqi 830011, Xinjiang Uyghur, Peoples R China
关键词
Gastroesophageal cancer; Gastric cancer; Neoadjuvant chemotherapy; Meta-analysis; ADVANCED GASTRIC-CANCER; PHASE-II TRIAL; PERIOPERATIVE CHEMOTHERAPY; PREOPERATIVE CHEMOTHERAPY; ESOPHAGOGASTRIC JUNCTION; ESOPHAGEAL CANCER; RANDOMIZED-TRIAL; SURGERY; ADENOCARCINOMA; CISPLATIN;
D O I
10.3748/wjg.v18.i48.7384
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
AIM: To investigate the effectiveness of 5-flurouracil-based neoadjuvant chemotherapy (NAC) for gastroesophageal and gastric cancer by meta-analysis. METHODS: MEDLINE and manual searches were performed to identify all published randomized controlled trials (RCTs) investigating the efficacy of the flurouracil-based NAC for gastroesophageal and gastric cancer, and RCTs of NAC for advanced gastroesophageal and gastric cancer vs no therapy before surgery. Studies that included patients with metastases at enrollment were excluded. Primary endpoint was the odds ratio (OR) for improving overall survival rate of patients with gastroesophageal and gastric cancer. Secondary endpoints were the OR of efficiency for down-staging tumor and increasing R0 resection in patients with gastroesophageal and gastric cancer. Safety analyses were also performed. The OR was the principal measurement of effect, which was calculated as the treatment group (NAC plus surgery) vs control group (surgery alone) and was presented as a point estimate with 95% confidence intervals (CI). All calculations and statistical tests were performed using RevMan 5.1 software. RESULTS: Seven RCTs were included for the analysis. A total of 1249 patients with advanced gastroesophageal and gastric cancer enrolled in the seven trials were divided into treatment group (n = 620) and control group (n = 629). The quality scores of the RCTs were assessed according to the method of Jadad. The RCT quality scores ranged from 2 to 7 (5-point scale), with a mean of 3.75. The median follow-up time in these studies was over 3 years. The meta-analysis showed that NAC improved the overall survival rate (OR 1.40, 95%CI 1.11-1.76; P = 0.005), which was statistically significant. The 3-year progression-free survival rate was significantly higher in treatment group than in control group (37.7% vs 27.3%) (OR 1.62, 95%CI 1.21-2.15; P = 0.001). The tumor down-stage rate was higher in treatment group than in control group (55.76% vs 41.38%) (OR 1.77, 95%CI 1.27-2.49; P = 0.0009) and the R0 resection rate of the gastroesophageal and gastric cancer was higher in treatment group than in control group (75.11% vs 68.56%) (OR 1.38, 95%CI 1.03-1.85; P = 0.03), with significant differences. No obvious safety concerns about mortality and complications were raised in these trials. There were no statistically significant differences in perioperative mortality (5.08% vs 4.86%) (OR 1.05, 95%CI 0.57-1.94; P = 0.87 fixed-effect model) and in the complication rate between the two groups (13.25% vs 9.66%) (OR 1.40, 95%CI 0.91-2.14; P = 0.12 fixed-effect model). Trials showed that patients from Western countries favored NAC compared with those from Asian countries (OR 1.40, 95%CI 1.07-1.83). Monotherapy was inferior to multiple chemotherapy (OR 1.40, 95%CI 1.07-1.83). Intravenous administration of NAC was more advantageous than oral route (OR 1.41, 95%CI 1.09-1.81). CONCLUSION: Flurouracil-based NAC can safely improve overall survival rate of patients with gastroesophageal/gastric cancer. Additionally, NAC can down the tumor stage and improve R0 resection. (C) 2012 Baishideng. All rights reserved.
引用
收藏
页码:7384 / 7393
页数:10
相关论文
共 35 条
[1]
Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer [J].
Biffi, Roberto ;
Fazio, Nicola ;
Luca, Fabrizio ;
Chiappa, Antonio ;
Andreoni, Bruno ;
Zampino, Maria Giulia ;
Roth, Arnaud ;
Schuller, Jan Christian ;
Fiori, Giancarla ;
Orsi, Franco ;
Bonomo, Guido ;
Crosta, Cristiano ;
Huber, Olivier .
WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (07) :868-874
[2]
Multimodal therapy in locally advanced gastric cancer [J].
Boelke, E. ;
Peiper, M. ;
Knoefel, W. T. ;
Baldus, S. E. ;
Schauer, M. ;
Matuschek, C. ;
Gerber, P. A. ;
Hoff, N. -P. ;
Budach, W. ;
Gattermann, N. ;
Erhardt, A. ;
Scherer, A. ;
Buhren, B. A. ;
Orth, K. .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (43) :2205-2211
[3]
Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries [J].
Botterweck, AAM ;
Schouten, LJ ;
Volovics, A ;
Dorant, E ;
van den Brandt, PA .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2000, 29 (04) :645-654
[4]
Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer [J].
Briasoulis, Evangelos ;
Liakakos, Theodore ;
Dova, Lefkothea ;
Fatouros, Michael ;
Tsekeris, Pericles ;
Roukos, Dimitrios H. ;
Kappas, Angelos M. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (06) :931-939
[5]
Epidemiology of gastric cancer [J].
Crew, Katherine D. ;
Neugut, Alfred I. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (03) :354-362
[6]
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[7]
Phase II Trial of Preoperative Chemotherapy with Docetaxel, Cisplatin and S-1 for T4 Locally Advanced Gastric Cancer [J].
Fushida, Sachio ;
Nashimoto, Atsushi ;
Fukushima, Norimasa ;
Kawachi, Yasuyuki ;
Fujimura, Takashi ;
Kuwabara, Shiro ;
Musha, Nobuyuki .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (02) :131-133
[8]
Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial [J].
Hartgrink, HH ;
van de Velde, CJH ;
Putter, H ;
Songun, I ;
Tesselaar, MET ;
Kranenbarg, EK ;
de Vries, JE ;
Wils, JA ;
van der Bijl, J ;
van Krieken, JHJM .
EJSO, 2004, 30 (06) :643-649
[9]
He Ling-Feng, 2008, Ai Zheng, V27, P407
[10]
Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer [J].
Inoue, K. ;
Nakane, Y. ;
Kogire, M. ;
Fujitani, K. ;
Kimura, Y. ;
Imamura, H. ;
Tamura, S. ;
Okano, S. ;
Kwon, A. H. ;
Kurokawa, Y. ;
Shimokawa, T. ;
Takiuchii, H. ;
Tsujinaka, T. ;
Furukawa, H. .
EJSO, 2012, 38 (02) :143-149